Lifecore Biomedical, Inc.
LFCR
$7.90
$0.070.89%
NASDAQ
| 09/30/2025 | 05/25/2025 | 02/23/2025 | 11/24/2024 | 08/25/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.92% | -3.81% | -1.54% | 8.01% | 0.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.92% | -3.81% | -1.54% | 8.01% | 0.75% |
| Cost of Revenue | 20.71% | 8.96% | 6.30% | 6.37% | -11.36% |
| Gross Profit | 44.63% | -19.05% | -17.23% | 11.32% | 97.47% |
| SG&A Expenses | -27.59% | -26.55% | 2.49% | 16.66% | 53.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.15% | -4.16% | 4.52% | 8.40% | 5.80% |
| Operating Income | 66.24% | 0.49% | -1,749.19% | -17.27% | -22.52% |
| Income Before Tax | 40.58% | 84.40% | -198.50% | -146.05% | -29.81% |
| Income Tax Expenses | 1,432.00% | 157.89% | -103.69% | 166.15% | -128.41% |
| Earnings from Continuing Operations | 38.44% | 83.81% | -199.89% | -146.14% | -28.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.44% | 83.81% | -194.48% | -146.22% | -50.92% |
| EBIT | 66.24% | 0.49% | -1,749.19% | -17.27% | -22.52% |
| EBITDA | 84.68% | -1.76% | -111.53% | 11.14% | -35.17% |
| EPS Basic | 44.52% | 76.15% | -191.55% | -154.26% | -48.71% |
| Normalized Basic EPS | 42.07% | 54.39% | -142.00% | -137.88% | -19.72% |
| EPS Diluted | 44.94% | 76.15% | -211.08% | -165.07% | -49.84% |
| Normalized Diluted EPS | 42.07% | 54.39% | -150.43% | -145.28% | -19.72% |
| Average Basic Shares Outstanding | 21.22% | 21.15% | 21.43% | 12.81% | 1.49% |
| Average Diluted Shares Outstanding | 21.22% | 21.15% | 1.12% | -5.65% | 1.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |